Access to phage therapy at Hospices Civils de Lyon in 2022: Implementation of the PHAGEinLYON Clinic program.

IF 4.9 2区医学 Q1 INFECTIOUS DISEASES International Journal of Antimicrobial Agents Pub Date : 2024-11-02 DOI:10.1016/j.ijantimicag.2024.107372

Tristan Ferry, Myrtille Le Bouar, Thomas Briot, Tiphaine Roussel-Gaillard, Thomas Perpoint, Sandrine Roux, Florence Ader, Florent Valour, Behrouz Kassai, Inesse Boussaha, Marietou Ndiaye, Fabien Craighero, Clément Javaux, Sébastien Lustig, Cécile Batailler

{"title":"Access to phage therapy at Hospices Civils de Lyon in 2022: Implementation of the PHAGEinLYON Clinic program.","authors":"Tristan Ferry, Myrtille Le Bouar, Thomas Briot, Tiphaine Roussel-Gaillard, Thomas Perpoint, Sandrine Roux, Florence Ader, Florent Valour, Behrouz Kassai, Inesse Boussaha, Marietou Ndiaye, Fabien Craighero, Clément Javaux, Sébastien Lustig, Cécile Batailler","doi":"10.1016/j.ijantimicag.2024.107372","DOIUrl":null,"url":null,"abstract":"Objectives: To describe the set-up in 2022 of the PHAGEinLYON Clinic program dedicated to improve access to phage therapy in France using pharmaceutical-grade phages.Methods: We described the process, prospectively collected all phage therapy requests received during 2022 and reviewed them retrospectively to analyze the decision and also the patient care pathway (NCT05883995).Results: Among 143 phage therapy requests, the indication was confirmed by multidisciplinary team meetings for 57 (40%) of them, and 44 were infected with bacteria that could be easily targeted by phages in France. Finally, 33 patients were treated, including 26 at our institution as compassionate use or in a clinical trial. Main indications were complex bone and joint infections, endovascular infections and lung infections. To manage these patients, 172 pharmaceutic phage cocktails targeting S. aureus and/or P. aeruginosa were prepared; 57 were dedicated to local, and 99 to intravenous injections. During the follow-up, 18 (69%) patients had a favorable clinical evolution, 6 (23%) required subsequent phage therapy, with the same phages with a greater phage exposition, or with different phages from elsewhere.Conclusions: The implementation of the PHAGEinLYON Clinic program in 2022 was associated with a groundbreaking access of phage therapy in France.","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":null,"pages":null},"PeriodicalIF":4.9000,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Antimicrobial Agents","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijantimicag.2024.107372","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To describe the set-up in 2022 of the PHAGEinLYON Clinic program dedicated to improve access to phage therapy in France using pharmaceutical-grade phages.

Methods: We described the process, prospectively collected all phage therapy requests received during 2022 and reviewed them retrospectively to analyze the decision and also the patient care pathway (NCT05883995).

Results: Among 143 phage therapy requests, the indication was confirmed by multidisciplinary team meetings for 57 (40%) of them, and 44 were infected with bacteria that could be easily targeted by phages in France. Finally, 33 patients were treated, including 26 at our institution as compassionate use or in a clinical trial. Main indications were complex bone and joint infections, endovascular infections and lung infections. To manage these patients, 172 pharmaceutic phage cocktails targeting S. aureus and/or P. aeruginosa were prepared; 57 were dedicated to local, and 99 to intravenous injections. During the follow-up, 18 (69%) patients had a favorable clinical evolution, 6 (23%) required subsequent phage therapy, with the same phages with a greater phage exposition, or with different phages from elsewhere.

Conclusions: The implementation of the PHAGEinLYON Clinic program in 2022 was associated with a groundbreaking access of phage therapy in France.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

2022 年里昂平民医院的噬菌体疗法：PHAGEinLYON 诊所计划的实施。

目的：介绍 2022 年 PHAGEinLYON 诊所计划的设立情况：描述 2022 年 PHAGEinLYON 诊所项目的设立情况，该项目致力于在法国推广使用医药级噬菌体进行噬菌体治疗：我们描述了这一过程，前瞻性地收集了2022年收到的所有噬菌体治疗申请，并对其进行回顾性审查，以分析决策和患者护理路径（NCT05883995）：在143份噬菌体治疗申请中，57份（40%）的适应症得到了多学科团队会议的确认，44份感染了法国噬菌体容易靶向的细菌。最后，33 名患者接受了治疗，其中 26 人在本机构接受了同情性使用或临床试验。主要适应症是复杂的骨关节感染、血管内感染和肺部感染。为治疗这些患者，我们配制了 172 种针对金黄色葡萄球菌和/或绿脓杆菌的药用噬菌体鸡尾酒；其中 57 种用于局部注射，99 种用于静脉注射。在随访过程中，18 名患者（69%）的临床疗效良好，6 名患者（23%）需要后续噬菌体治疗，使用相同的噬菌体，但噬菌体暴露量更大，或使用其他地方的不同噬菌体：结论：2022 年 PHAGEinLYON 诊所项目的实施为噬菌体疗法在法国的普及开创了先河。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International Journal of Antimicrobial Agents 医学-传染病学

CiteScore

21.60

自引率

0.90%

发文量

176

审稿时长

36 days

期刊介绍： The International Journal of Antimicrobial Agents is a peer-reviewed publication offering comprehensive and current reference information on the physical, pharmacological, in vitro, and clinical properties of individual antimicrobial agents, covering antiviral, antiparasitic, antibacterial, and antifungal agents. The journal not only communicates new trends and developments through authoritative review articles but also addresses the critical issue of antimicrobial resistance, both in hospital and community settings. Published content includes solicited reviews by leading experts and high-quality original research papers in the specified fields.